Semaglutide vs Tirzepatide vs Retatrutide: Comparing the Three Research Peptides
Semaglutide, tirzepatide, and retatrutide are the three incretin research peptides most often lined up next to each other, and for good reason: they form a clean progression. One targets a single receptor, the next targets two, and the third targets three. This pillar looks at the peptides as research subjects in their own right - their receptor targets, the mechanism ladder they climb, their reported half-lives, and how mature the research literature around each one is. The framing here is laboratory investigation, not medicine.
A quick note on the brand connection, made once: the molecules behind two of these peptides are also the active ingredients in approved medicines. Semaglutide is the molecule in Ozempic and Wegovy (trademarks of Novo Nordisk), and tirzepatide is the molecule in Mounjaro and Zepbound (trademarks of Eli Lilly). Retatrutide has no approved brand and remains investigational. Those trademarks are named only to orient readers. A branded medicine and a research peptide are different categories and are not interchangeable, and everything below concerns the research-use-only compounds.
| Compound | Class | Receptors | Approximate half-life | Research maturity |
|---|---|---|---|---|
| Semaglutide | Mono-agonist | GLP-1 | About 7 days (reported near 165 hours) | Extensive literature; molecule underlies approved medicines |
| Tirzepatide | Dual-agonist | GIP and GLP-1 | About 5 days (reported near 120 hours) | Substantial literature; molecule underlies approved medicines |
| Retatrutide | Triple-agonist | GIP, GLP-1, and glucagon | About 6 days (reported in early research) | Earlier stage; investigational, no approved brand |
The mechanism ladder
The cleanest way to hold these three in mind is as a ladder of receptor targeting. Semaglutide is a mono-agonist. It engages the GLP-1 receptor alone, and GLP-1 signalling is studied for glucose-dependent insulin release, glucagon suppression, and slowed gastric emptying. It is the baseline rung.
Tirzepatide adds a rung. It is a dual-agonist that engages the GLP-1 receptor and the GIP receptor together. GIP is the second major incretin hormone, and combining both incretin arms in one molecule is the design idea researchers examine when they study it. Retatrutide adds a third rung by bringing in the glucagon receptor alongside GIP and GLP-1, making it a triple-agonist. The glucagon arm is distinct because it is not an incretin receptor at all; preclinical work has examined how glucagon-receptor agonism may relate to energy expenditure while the incretin arms handle insulin and appetite signalling. The receptor biology behind all three is laid out in our incretin receptor overview.
Structure and half-life
Semaglutide is a 31-amino-acid peptide; tirzepatide is a 39-amino-acid peptide; retatrutide is a further engineered multi-agonist. All three carry a fatty-acid modification that promotes albumin binding, which is the structural reason each has a long circulating half-life measured in days rather than minutes. The reported figures - roughly seven days for semaglutide, around five for tirzepatide, and near six for retatrutide in early research - are approximate and drawn from the literature rather than fixed constants. For researchers, that long half-life is a defining pharmacokinetic feature and a frequent subject of study in its own right.
Research maturity
The three peptides sit at different points on the research timeline. Semaglutide has the deepest and longest body of published work behind it, and its molecule underlies medicines that have been studied for years. Tirzepatide follows with a substantial and fast-growing literature. Retatrutide is the newest of the three: it is investigational, has no approved brand, and its research base, while expanding, is earlier stage than the other two. That gradient - most mature, substantial, earliest - tracks the same order as the receptor ladder, which is part of why the trio is so often taught together.
Sourcing and handling at the bench
As research materials, all three arrive as lyophilised powder in a vial and are reconstituted with bacteriostatic water for in-vitro or preclinical work, with identity and purity documented by a certificate of analysis. Working out concentration - milligrams of peptide against millilitres of diluent, and the resulting micrograms per unit volume - is a standard bench exercise. Our reconstitution calculator handles that math. Research-grade material for each compound is available: semaglutide, tirzepatide, and retatrutide, with the full range on the store page.
Going deeper on the pairs
This three-way view is the overview; the pairwise comparisons add detail. For the mono-versus-triple contrast, see semaglutide versus retatrutide. For the dual-versus-triple step, see tirzepatide versus retatrutide.
The short version
Semaglutide is a GLP-1 mono-agonist, tirzepatide is a dual GIP and GLP-1 agonist, and retatrutide is a triple GIP, GLP-1, and glucagon agonist. They form a one-two-three receptor ladder, all share a long multi-day half-life, and they descend in research maturity from most established to earliest stage. As research peptides they are laboratory subjects only. Nothing here is a dosing schedule or a substitute for a prescribed medicine, and any treatment decision belongs with a licensed healthcare professional.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.